CA2298107A1 - Use of transcription factor brn-3a - Google Patents

Abstract

The present invention provides a polypeptide comprising transcription factor Brn-3a or a derivative thereof for use in a method of treatment of the human or animal body by therapy.

Description

USE OF TRANSCRIPTION FACTOR IiRN-3A
Field of the invention This invention relates to the use of transcription factor Brn-3a and derivatives s thereof.
B_ ackaround to the invention During the normal development of the nervous system, a high proportion of the neurons which initially form undergo programmed cell death or apoptosis. Such cell to death is essential for the normal development of the nervous system and is an active process in which the cell effectively commits suicide in an energy dependent process. It is thus distinct from necrotic death induced by toxic or noxious agents which does not normally occur in the developing nervous system.
Although essential for normal development, excessive cell death is also 15 characteristic of a number of human neurological diseases. Thus, several inherited diseases such as familial dysautonomia or infantile spinal muscular atrophy involve enhanced programmed cell death during development resulting in reduced numbers of specific neuronal cell types remaining. Similarly, progressive enhanced neuronal cell death is characteristic of amyotrophic lateral sclerosis (motor neuron disease) and the late 20 onset neurodegenerative diseases such as Alzheimer's and Parkinson's diseases where it is responsible for the progressive neurological lesions which develop.
As well as its role in normal development and in congenital or chronic diseases, programmed cell death is also involved in the response of the nervous system to acute injury. Thus, for example, following spinal injury, the initial death of a number of

2 s neurons by necrosis is followed by a subsequent wave of apoptosis that results in the death of further neurons. It is the loss of many neurons in this way coupled with the failure of the remaining neurons to regenerate their axons, which results in the motor and sensory impairment suffered by human spinal injury patients with permanent paralysis below the injured area. Thus, programmed cell death plays a key role in congenital, acute 3o and chronic diseases of the nervous system. An understanding of the mechanisms of this process and in particular, the identification of the means of controlling and manipulating it would therefore be invaluable in developing new methods of treating such diseases.
The three members of the Brn-3 family of transcription factors, Brn-3a, Brn-3b _ _2_ and Brn-3c. are expressed in distinct but overlapping sets of neurons in the developing and adult nervous systems (Fedtsova et al., 199G). Brn-3a, Brn-3b and Brn-3c are members of the POU (Pit-Oct-Unc) family of transcription factors originally defined on the basis of a common DNA-binding POU domain found in the mammalian transcription s factors Pit-1, Oct-1 and Oct-2 and in the nematode factor Unc-86. The original members of this family are known to play a key role in the development of specific neuronal cell types with the Pit-1 factor being essential for the development of the pituitary gland whilst the unc-86 mutation results in the absence of specific neuronal cell types in the nematode. The observation that all three isoforms of Bm-3 are differentially expressed io during mouse neural development suggests roles for these proteins in the regulation of phenotypic changes that occur during neuronal differentiation.
Brn-3a, Brn-3b and Brn-3c show close homology to each other within the DNA-binding POU domain but much less homology outside it, and are encoded by three different genes (Theil et al., 1993 & 1994). Brn-3a is expressed as two different splice i5 variants. The short form, Brn-3aS lacks the N-terminal 84 amino acids of the full-length form, Brn-3aL.
Summary of the invention The present invention is based on our finding chat over expression of transcription 2o factor Brn-3a can protect neuronal cells from apoptosis. We have also shown that Brn-3a activates specifically expression of the Bcl-2 gene in neuronal cells and that this activation is mediated via a Brn-3a response element in the 5' regulatory region of the Bcl-2 gene. Irnportantly, our data indicate that both the anti-apoptotic effect of Brn-3a and its ability to activate expression of Bcl-2 appear to be mediated by the N-terminal 25 domain which is present in the full-length Brn-3aL but not in the truncated Brn-3aS.
The members of the Bcl-2 family, which include Bcl-2, Bcl-xL, Bad and Bax, perform critical roles in the regulation of selective apoptosis during development of the nervous system. The stimulation of Bcl-2 expression by Brn-3a in a neuron-specific manner and consequent protection of neuronal cells from apoptosis suggests that Brn-3a

3 o may co-ordinate some aspects of neuronal reorganisation during development and following injury. Thus, the elevation of Brn-3a expression by either pharmacological or by gene therapy procedures represents a potential method for treating human diseases involving excessive neuronal death and/or lack of nerve regeneration.

Accordingly, the present invention provides a polypeptide comprising transcription factor Brn-3a or a derivative thereof for use in a method of treatment of the human or animal body by therapy. Preferably, said derivative of Brn-3a comprises an N-terminal fragment, more preferably the N-terminal 84 amino acids of the full-length s form of Brn-3a. More preferably, said derivative possesses anti-apoptotic activity but not neurite outgrowth stimulating activity.
The present invention further provides a polynucleotide encoding said Brn-3a or derivative thereof for use in a method of treatment of the human or animal body by therapy. The present invention also provides a nucleic acid vector comprising a i o poiynucleotide encoding said Brn-3a or derivative thereof operably linked to regulatory sequences permitting expression of Brn-3a or a derivative thereof in a host cell.
Preferably the host cell is a cell of the central or peripheral nervous system of an animal, more preferably a mammal, including primates and humans.
The nucleic acid vectors of the present invention may also comprise mammalian 15 genomic sequences flanking said polynucleotide and regulatory sequences to allow introduction of the polynucleotide into the genome of a mammalian cell by homologous recombination. Preferably said mammalian genomic sequences are derived from the human genome. The vectors may also comprise viral genomic sequences flanking said polynucleotide and regulatory sequences to allow construction of viral strains which 2o comprise a polynucleotide encoding said Brn-3a or derivative thereof.
Preferably said viral genomic sequences are derived from the genome of a herpes simplex virus.
Thus the present invention further provides a viral strain comprising a polynucleotide encoding Brn-3a or a derivative thereof operably linked to regulatory sequences permitting expression of said Brn-3a or derivative thereof in a host cell, for use 2 s in a method of treatment of the human or animal body by therapy.
Preferably said viral strain is a herpes simplex virus.
Delivery of the polynucleotides, vectors or viral strains of the invention to a host cell may be enhanced by combining them with a transfection agent. Such transfection agents include cationic agents (for example calcium phosphate and DEAF-dextran) and 0 liposome compositions (for example LipofectinTM and Transfectam~). Thus the present invention also provides a composition comprising a polynucleotide, a vector or a viral strain of the invention together with a transfection agent, for use in a method of treatment of the human or animal body by therapy.

-4-Treatment of neurodegenerative diseases and nerve injuries may require administration of additional therapeutic polypeptides. For example, neurotrophic factors including nerve growth factor (NGF), ciliary neurotrophic factor (CNTF), brain-derived neurotrophic factor (BNTF) and neurotrophins (such as NT-3, NT-4/5) have potential as therapeutic agents for the treatment of Parkinson's disease. Thus the present invention provides a composition comprising a polypeptide according to the invention and at least one other therapeutic polypeptide, for use in a method of treatment of the human or animal body by therapy.
The therapeutic polypeptide may also be administered in the form of a to polynucleotide encoding said therapeutic polypeptide and said polynucleotide may form part of a nucleic acid vector or viral strain in the same manner as for the polynucleotide encoding Brn-3a or a derivative thereof.
Diseases which may be treated using the polypeptides, polynucleotides, vectors, viral strains and compositions of the invention include diseases of the peripheral or 15 central nervous system such as neurodegenerative diseases and damage to nervous tissue as a result of injuryltrauma. In particular, neurodegenerative diseases include motor neurone disease, several inherited diseases, such as familial dysautonomia and infantile spinal muscular atrophy, and late onset neurodegenerative diseases such as Parkinson's and Alzheimer's diseases.
2o The polypeptides, polynucleotides, vectors, viral strains and compositions of the invention may in particular be used in preventing apoptosis in a cell of the peripheral or central nervous system of a human or animal and/or in enhancing nerve regeneration following damage, typically due to injury.
2s Brief description of the figures Figure 1 shows graphs comparing cell survivaUapoptosis in the presence or absence of Brn-3a over expression.
Figure 2a illustrates the constructs used in this study.
3o Figure 2 b depicts graphs of cell survival for cells expressing different Brn-3a constructs.
Figure 3a is a Western blot of ND7 cell extracts showing the levels of Bcl-2 and Bad in response to Brn-3a expression.
Figure 3b is a graph depicting Bcl-2 expression in response to over expression of Brn-3a.

-S-Figure 4a illustrates the 5' end of the Bcl-2 I;ene.
Figures 4b,c show the results of reporter gene assays using different Brn-3a constructs.
Figure 5 shows the results of reporter gene assays using different Bcl-2 promoter constructs.
s Figure 6 shows the results of reporter gene assays using different Brn-3 factors and a region of the Bcl-2 promoter.
Figure 7 depicts graphs of cell survival in the presence or absence of Brn-3a.
Figure 8 shows the survival of trigemina! ganglion neurons obtained from various stages of embryonic development, in the presence or absence of Brn-3a over expression.
i o Figure 9 shows the survival of trigeminal ganglion neurons obtained from various stages of embryonic development, in the presence or absence of an anti-sense Brn-3a vector.
Detailed description of the invention ~ 5 A. Polypeptides Polypeptides of the invention comprise transcription factor Brn-3a and derivatives thereof. Both marine and human forms of Brn-3a have been cloned and their nucleotide and amino acid sequences determined. The human Brn-3a sequence is published in Xiang et ul., 1995 (Genbank accession numbers U10062/U10063/ U09783) and is shown in 2o SEQ. ID. Nos. I and 2. The sequence of marine Brn-3a is published in Theil et al., 1994 (Genbank accession number S69350) and is shown in SED. ID. Nos. 3 and 4 (The introns have been removed from SEQ. ID. No. 3).
Thus a polypeptide of the invention comprises the amino acid sequence set out in SEQ ID Nos. 2 or 4 or a substantially homologous sequence, or of a fragment of either of 25 these sequences. In general, the naturally occurring human or marine Brn-3a amino acid sequence shown in SEQ .ID Nos. 2 and 4, respectively, are preferred. However, the polypeptides of the invention include derivatives of the natural human or marine Brn-3a sequences. The term derivative is taken to encompass all homologues and allelic variants having substantial homology to the human or marine Brn-3a sequences set out in SEQ
so ID. Nos. 2 and 4. It is also taken to include fragments which possess anti-apoptotic activity of the human or marine Brn-3a sequences set out in SEQ ID. Nos. 2 and 4, and of their homologues and allelic variants. In particular, preferred derivatives will comprise an amino acid sequence having substantial homology to the N-terminal 84 amino acids present in the tull-length splice variant of mouse Brn-3a (amino acids l to 84 of SEQ. ID.
No. 4 encoded by nucleotides 1 to 234 of SEQ. ID. No. 3) or human Brn-3a (amino acids 1 to 84 of SEQ. ID. No. 2 encoded by nucleotides 1 to 234 of SEQ. ID. No 1).
It should be noted that the N-terminal 98 amino acids of mouse and human Brn-3a are identical, s with only one difference in the next 37 residues up to amino acid 135. Thus the N-terminal region of Brn-3a is highly conserved between mice and humans.
An allelic variant will be a variant which will occur naturally in a human or mouse and which will function in a substantially similar manner to the polypeptide of SEQ ID Nos. 2 or 4. In particular, it will have anti-apoptotic activity.
Similarly, a io species homologue of the protein will be the functionally equivalent polypeptide which occurs naturally in another species. Such a homologue may occur in animals such as mammals (e.g. rats or rabbits), especially primates. Within any one species, a homologue may exist as several allelic variants, and these will all be considered homologues of the protein of SEQ ID Nos. 2 and 4.
is Allelic variants and species homologues can be obtained using standard procedures. In particular, it will be possible to use a Brn-3a nucleotide sequence to probe libraries made from mammalian cells to obtain clones encoding the allelic or species variants. The clones can be manipulated by conventional techniques to identify a polypeptide of the .invention which can then be produced by recombinant or synthetic 2o techniques known per se. Preferred species homologues include primate species homologues.
A protein at least 70% homologous to the polypeptide of SEQ ID Nos. 2 or 4 or an allelic variant or species homologue thereof will be preferably at least 80 or 90% and more preferably at least 95%, 97% or 99% homologous thereto over a region of at least 2 s 20, preferably at least 30, for instance at least 40, 60 or 100 or more contiguous amino acids. In particular, an allelic variant or species homologue will be at feast 90, 95%, 97%
or 99% homologous over the N-terminal domain of at least 40, 60 or 100 contiguous amino acids. Methods of measuring protein homology are well known in the art and it will be understood by those of skill in the art that in the present context, homology is 3o calculated on the basis of amino acid identity (sometimes referred to as "hard homology").
Further, the sequence of the polypeptide of SEQ ID Nos. 2 and 4 and of allelic variants and species homologues can be modified to provide polypeptides of the invention. Amino acid substitutions may be made, for example from 1. 2 or 3 to 10, 2U or 30 substitutions provided that the modified polypeptide retains anti-apoptotic activity.
Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:
Derivatives of the polypeptides of the invention will preferably also possess neurite outgrowth stimulating activity. We have shown that this activity is primarily located in the C-terminal DNA-binding POU domain. Thus the polypeptides of the invention preferably comprise a domain having substantial homology to the C-terminal 1 o DNA-binding POU domain of human or marine Brn-3a , more preferably comprising approximately amino acids 302 to 416 as set out in SEQ ID. Nos 2 or 4.
ALIPHATIC Non-polar G A P

ILV

Polar - uncharged C S T M

NQ

Polar - charged D E

KR

AROMATIC H F W Y

We have also shown that specific mutations in the N-terminal domain and C-terminal domain of Brn-3a can abolish the anti-apoptotic and neurite outgrowth stimulating activity of Brn-3a, respectively. Thus it is possible to prepare polypeptides which lack one of these activities by mutagenesis techniques including substitutions, insertions and deletions. In particular, an amino acid substitution of valine by isoleucine at position 22 of the homeodomain of marine Brn-3a (residue 380 of SEQ. ID.
No. 4, 2o equivalent to residue 378 of SEQ. ID. No. 2) significantly reduces the neurite outgrowth stimulating activity of Brn-3a. This may also be achieved by replacing ttie c:-terminal domain of Brn-3a with the equivalent C-terminal domain of Brn-3b (which has an isoleucine residue at position 22 of the homeodomain in place of a valine residue).
Further, deletion of the N-terminal domain of Brn-3a present in the full-length splice _g_ variant hut not the short variant abolishes the ability of Brn-3a to inhibit apoptosis.
Alternatively, derivatives of Brn-3a which possess anti-apoptotic activity but not neurite outgrowth stimulating activity may be prepared by fusing the N-terminal domain of Brn-3a to a heterologous DNA binding domain, typically a POU domain, capable of binding to the promoter region of the bcl-2 gene. The preparation and testing of such a fusion protein can be performed using routine techniques of molecular biology.
Thus the polypeptides of the invention may be used to prepare a variety of therapeutic reagents which can either stimulate neurite outgrowth or inhibit apoptosis, or both. Preferably, the polypeptides of the invention exert specifically their effects in i o neuronal cells, more preferably in sensory or motor neuronal cells.
Polypeptides of the invention may be in a substantially isolated form. It will be understood that the polypeptide may be mixed with carriers or diluents which will not interfere with the intended purpose of the polypeptide and still be regarded as substantially isolated. A polypeptide of the invention may also be in a substantially s purified form, in which case it will generally comprise the polypeptide in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the polypeptide in the preparation is a polypeptide of the invention.
Polypeptides of the invention may be made by synthetic means or recombinantly using techniques well known to skilled persons.
2o Polypeptides of the invention may be used in in vitro or in vivo cell culture systems to study the role of Bm-3a, and its homologues in disease. For example, truncated or modified Brn-3a may be introduced into a cell to disrupt the normal functions which occur in the cell. The polypeptides of the invention may be introduced into the cell by in situ expression of the polypeptide from a recombinant expression vector (see below). The 2 s expression vector optionally carries an inducible promoter to control the expression of the polypeptide.
The use of mammalian host cells is expected to provide for such post-translational modifications (e.g. myristolation, glycosylation, truncation, lapidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on 3o recombinant expression products of the invention. Such cell culture systems in which polypeptide of the invention are expressed may be used in assay systems to identify candidate substances which interfere with or enhance the functions of the polypeptides of the invention in the cell.

_g_ I3. Assayins~ anti-apoptotic and neurite outgrowth stimulating activity The derivatives discussed above can be tested for anti-apoptotic and neurite outgrowth stimulating activity using the following assay methods.
s Anti-apoptotic activity Typically, ND7 cells can be used as a model system for determining if derivatives of Brn-3a inhibit apoptosis. Apoptosis can be induced in ND7 cells by transferring the cells to serum free media, optionally containing retinoic acid (RA).
The induction of apoptosis can be determined by various means. There are several ~ o techniques known to a skilled person for determining if cell death is due to apoptosis.
Apoptotic cell death is characterised by morphological changes which can be observed by microscopy, for example cytoplasmic blebbing, cell shrinkage, internucleosomal fragmentation and chromatin condensation. DNA cleavage typical of the apoptotie process can be demonstrated using TLJNEL assays and DNA ladder assays (see Materials and i5 Methods, Gavreili et al., 1992).
Typically, the derivative of Brn-3a is stably integrated in the genome of ND7 cells.
This can be achieved by transfecting cells with a nucleic acid encoding the Brn-3a under the control of a suitable promoter (for example the mouse mammary tumour virus (MMTV) promoter) as well as a selective marker, for example the neomycin resistance gene. A
2o certain population will take up the nucleic acid and a subpopulation of these will integrate the nucleic acid into their genome. These stable clones can subsequently be selected (in the case of the marker being the neomycin resistance gene, by the addition on geneticin (G418) to the culture medium).
Preferably, the apoptotic response to serum starvation/RA is reduced in the presence 2s of the derivative by at least 25% relative to the apoptotic response in the absence of derivative, more preferably by at least 50% or 75%. So, for example, if the percentage cell survival of ND7 cells in the absence of the derivative is 20%, then the percentage cell survival in the presence of the derivative is preferably greater than 40%, more preferably greater than 60% or 80%.
Neurite outgrowth stimulating activity Typically, ND7 cells can be used as a model system for determining if derivatives of Brn-3a stimulate neurite outgrowth. Neurite outgrowth length can be determined using immunocytochemical techniques (as described in Smith et crl., 1997 a.b). Cells are incubated with a primary antibody to a-tubulin with detection using the peroxidase-diaminobenzidene colour reaction. The length of the longest process for each of 400 cells is then determined for each sample using video capture NIH Image software (version 1.59).
A construct expressing the derivative, under the control of an inducible promoter (for example the MMTV promoter inducible with dexamethasone), is stably integrated into the genome of the ND7 cells as described above. A control vector lacking sequences encoding the derivative is used as a control. The number and lengths of processes formed in the absence or presence of the inducer {for example 1 p,M dexamethasone) is then 1 o measured for cells transfected with the control vector versus cells transfected with the derivative-expressing vector.
Preferably, the percentage number of cells with neurites in the presence of the derivative is increased by at least 50% relative to the percentage number of cells with neurites with the control vector alone, more preferably by at least 75% or 100%. Preferably, i s the average neurite length of cells in the presence of the derivative is increased by at least 50% relative to the average neurite length of cells with the control vector alone, more preferably by at least 75% or 100%.
C. Polynucleotides and vectors.
2o Polynucleotides of the invention comprise nucleic acid sequences encoding the polypeptides of the invention. Polynucleotides of the invention may comprise DNA or RNA. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of 2 s acridine or polylysine chains at the 3' and/or 5' ends of the molecule.
For the purposes of the present invention, it is to be understood that the polynucleotides described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or life span of polynucleotides of the invention. In a preferred embodiment of the invention, the polynucleotide comprises the nucleic acid sequence as s o shown in SEQ ID No. 1 or SEQ ID. No. 3.
Preferred polynucleotides of the invention also include polynucleotide encoding any of the polypeptides of the invention described above. It will be understood by a skilled person that numerous different polynucleotides can encode the same polypeptide as a result w0 99105272 PCT/GB98102228 of the degeneracy of the genetic code.
Poiynucleotides of the invention comprise can be incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus in a further embodiment, the invention provides a method of making s polynucleotides of the invention by introducing a polynucleotide of the invention into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells include bacteria such as E.
coli, yeast, mammalian cell lines and other eukaryotic cell lines, for example insect Sf9 cells.
1 o Preferably, a polynucleotide of the invention in a vector is operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding 1 s sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences.
Such vectors may be transformed or transfected into a suitable host cell as described above to provide for expression of a polypeptide of the invention. This process may comprise culturing a host cell transformed with an expression vector as described above 2o under conditions to provide for expression by the vector of a coding sequence encoding the polypeptides, and optionally recovering the expressed polypeptides.
The vectors may be for example, plasmid or virus vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable 2 s marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a neomycin resistance gene for a mammalian vector. Vectors may be used in vitro, for example for the production of RNA or used to transfect or transform a host cell. The vector may also be adapted to be used in vivo, for example in a method of gene therapy. in particular viral vectors may be used as described below.
3o Promoterslenhancers and other expression regulation signals may be selected to be compatible with the host cell for which the expression vector is designed. For example, mammalian promoters, such as [3-actin promoters, may be used. Tissues-specific promoters, in particular neuronal cell specific promoters (for example the tyrosine hydroxylase (TH), L7, or neuron specific enolase (NSE) promoters), are c;specially preferred.
Promoters which are specific for particular neuronal cell types, for example sensory or motor neurons are especially preferred. Viral promoters may also be used, for example the Moloney marine leukaemia virus long terminal repeat (MMLV LTR), the promoter rous s sarcoma virus (RSV) LTR promoter, the SV40 promoter, the human cytomegalovirus (CMV) IE promoter, herpes simplex virus promoters or adenovirus promoters. All these promoters are readily available in the art.
D. Viral vectors 1 o The polynucleotides of the invention may be used in the form of a naked nucleic acid construct. Alternatively, they may be introduced into a variety of nucleic acid vectors. Such vectors include plasmids and viral vectors, preferably herpes simplex virus vectors. Vectors may further include sequences flanking a polynucleotide of the invention which comprise sequences homologous to eukaryotic genomic sequences, i s preferably mammalian genomic sequences, or viral genomic sequences. This will allow the introduction of the polynucleotides of the invention into the genome of eukaryotic cells or viruses by homologous recombination. In particular, a plasmid vector comprising the expression cassette flanked by viral sequences, preferably HSV 1 or HSV2 sequences, can be used to prepare a viral vector, preferably an HSV vector, suitable for delivering the 2o polynucleotides of the invention to a mammalian cell. This is described in further detail below for the herpes simplex virus. However the techniques employed are well-known to a skilled person and will be suitable for other viruses such as adenoviruses.
Other examples of suitable viral vectors include viral vectors able to integrate their genomes into the host cell genome, for example retroviruses, including lentiviruses, and adeno-2 s associated virus.
Herpes Simplex Virus Vectors 1. Viral Strains 3o The viral strains of the invention comprising a golynucleotide encoding Brn-3a or a derivative thereof may be derived from, for example, HSV 1 or HSV2 strains or derivatives thereof, preferably HSV 1. Derivatives include inter-type recombinants containing DNA from HSV 1 and HSV2 strains. Derivatives preferably have at least 80%
*rB

sequence homology to either the I-ISV 1 or HSV2 genomes, more preferably at least 90%.
even more preferably 95%.
The use of HSV strains in therapeutic procedures will require the strains to be attenuated so that they cannot establish a lytic cycle. In particular, if the HSV vectors are to be used for gene therapy in humans the polynucleotide of the invention should preferably be inserted into an essential gene. This is because if a vector virus encounters a wild-type virus transfer of the polynucleotide of the invention to the wild-type virus could occur by recombination. However as long as the polynucleotide of the invention is inserted into an essential gene this recombinational transfer would also delete the i o essential gene in the recipient virus and prevent 'escape' of the heterologous gene into the replication competent wild-type virus population.
Attenuated strains which may be used to produce HSV strains suitable for use in gene therapy, given as examples only, include strains that have mutations in ICP34.5 or ICP27, for example strain 1716 (MacLean et al., 1991), strains 83616 and 84009 (Chou i s and Roizman, 1992) and 8930 (Chou et al. , 1994) all of which have mutations in ICP34.5, and d27-1 (Rice and Knipe, 1990) which has a deletion in ICP27.
Strains deleted for both ICP34.5 and ICP27 may also be used, as disclosed in UK
Application No. 9615794.6. Alternatively, ICP4, ICPO, ICP22, VHS or gH, with an inactivating mutation in VMW65, or with aizy combination of the above may also be used to produce 2 o the HSV strain of the invention.
The terminology used in describing the various HSV genes is as found in Coffin and Latchman, 1996.
2. Complementing cell lines 25 HSV viruses defective in ICP27 are propagated in a cell line expressing ICP27, for example V27 cells (Rice and Knipe, 1990), 2-2 cells (Smith et al., 1992) or B130/2 cells, preferably B 130/2 cells (see below).
ICP27-expressing cell lines can be produced by co-transfecting mammalian cells, for example the Vero or BHK cells, with a vector, preferably a plasmid vector, 3o comprising a functional HSV ICP27 gene capable of being expressed in said cells, and a vector, preferably a plasmid vector, encoding a selectable marker, for example neomycin resistance. Clones possessing the selectable marker are then screened further to determine which clones also express functional ICP27, for example on the basis of their ability to support the growth of iCP?7- mutant HSV strains, using methods known to those skilled in the art (for example as described in Rice and Knipe, 1990).
A suitable complementing cell line (B 130/2) allowing growth of ICP27 deleted viruses and having no overlap between the complementing sequences and the s deleted viruses above (and thus preventing repair of ICP27 by homologous recombination during virus growth) is described in UK patent application no. 9615794.6.
B130/2 was generated by co-transfection of plasmid pSG130BS (Sekulovich et al., 1988) DNA
with neomycin resistance-encoding plasmid pMamNeo (Invitrogen) into BHK cells and the selection of neomycin resistant clones. A clone (B 130/2) highly permissive for the to growth of an HSV-I ICP27 deletion mutant was selected for virus growth.

carries a BamHI/SacI fragment from HSV-1 (nts 113322-115743) encoding the complete ICP27 coding sequence and part of UL55.
Cell lines which do not allow reversion of an ICP2T mutant HSV strain to a strain with functional ICP27 are produced as described above, ensuring that the vector 15 comprising a functional ICP27 gene does not contain sequences that overlap with (i.e. are homologous to) sequences remaining in the ICP2T mutant virus.
Where HSV strains comprise inactivating modifications in other essential genes, for example ICP4, complementing cell lines will further comprise a functional HSV gene which complements the modified essential gene in the same manner as described for 2o ICP27.
3. Methods of mutation HSV genes may be rendered functionally inactive by several techniques well known in the art. For example, they may be rendered functionally inactive by deletions, 2 s substitutions or insertions, preferably by deletion. Deletions may remove portions of the genes or the entire gene. Inserted sequences may include the expression cassette described above.
Mutations are made in the HSV strains by homologous recombination methods well-known to those skilled in the art. For example, HSV genomic DNA is transfected s o together with a vector, preferably a plasmid vector, comprising the mutated sequence flanked by homologous HSV sequences. The mutated sequence may comprise deletions, insertions or substitutions, all of which may be constructed by routine techniques.
Insertions may include selectable marker genes, for example lacZ, for screening recombinant viruses by, for example, ~i-galactosidase activity.
Mutations may also be made in other HSV genes, for example IE genes such as ICPO, ICP4, ICP6, ICP22, ICP47or VMW65, preferably ICP4 and VMW65. In the case of the VMW65 gene, the entire gene is not deleted since it encodes an essential structural protein, but a small inactivating insertion is made which abolishes the ability of VMW65 to transcriptionally activate IE genes (Ace et x1.,1989).
4. HSV strains comprising the expression cassette A polynucleotide of the invention may be inserted into the HSV genome at any i o location provided that the virus can still be propagated, which may require the use of a cell line carrying another HSV essential gene (as described in 2.) if the polynucleotide is inserted into an essential gene. For example, if the polynucleotide is inserted into the ICP27 gene of the HSV strain, then a cell-line expressing ICP27 would be needed. The polynucleotide is preferably inserted into the region of the ICP27 mutation as in the unlikely event that the mutation is repaired by recombination with a wild-type virus, the repair would remove the inserted polynucleotide.
The polynucleotide of the invention may be inserted into the HSV genome by homologous recombination of HSV strains with, for example, plasmid vectors carrying the polynucleotide flanked by HSV sequences, as described above for introducing 2o mutations. The polynucleotide may be introduced into a suitable plasmid vector comprising HSV sequences using cloning techniques well-known in the art.
E. Therapeutic polypeptides Treatment of diseases using the polypeptides, polynucleotide and vectors of the invention may be improved by administering additional therapeutic polypeptides. For example, neurotrophic factors including nerve growth factor (NGF), ciliary neurotrophic factor (CNTF), brain-derived neurotrophic factor (BNTF) and neurotrophins (such as NT-3, NT-4/5) have potential as therapeutic agents for the treatment of Parkinson's disease The therapeutic polypeptide may also be administered in the form of a 3o polynucleotide encoding said therapeutic polypeptide and said polynucleotide may form part of a nucleic acid vector or viral strain in the same manner as for the polynucleotide encoding Brn-3a or a derivative thereof.

F. Administration The polypeptides, polynucleotides and vectors of the invention, optionally with an additional therapeutic polypeptide or nucleic acidlvector encoding said therapeutic polypeptide, may thus be administered to a human or animal in need of treatment.
Diseases which may be treated using the polypeptides, polynucleotides, vectors, viral strains and compositions of the invention include diseases of the peripheral or central nervous system such as neurodegenerative diseases and damage to nervous tissue as a result of injury/trauma (including strokes). In particular, neurodegenerative diseases include motor neurone disease, several inherited diseases, such as familial dysautonomia 1 o and infantile spinal muscular atrophy, and late onset neurodegenerative diseases such as Parkinson's and Alzheimer's diseases.
The polypeptides of the invention and compositions comprising polypeptides of the invention together with at least one therapeutic polypeptide may be administered by direct injection into the site to be treated, for example tissue of the nervous system.
Preferably the polypeptides are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration. Typically, each poIypeptide is administered at a dose of from 0.01 to 30 mg/kg body weight, preferably from 0.1 to 10 mg/kg.
The polynucleotides of the invention may be administered directly as a naked nucleic acid construct, preferably further comprising flanking sequences homologous to the host cell genome. Uptake of naked nucleic acid constructs by mammalian cells is enhanced by several known transfection techniques for example those including the use of transfection agents. Example of these agents include cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectamTM
and transfectam~ ). Typically, nucleic acid constructs are mixed with the transfection agent to produce a composition.
Preferably the naked nucleic acid construct, viral vector comprising the 3o polynucleotide or composition is combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration.
The pharmaceutical composition is administered in such a way that the polynucleotide of the invention, viral vector for gene therapy, can be incorporated into cells at an appropriate area. For example, when the target of gene therapy is the central or peripheral nervous system and the polynucleotide of the invention is to be delivered by a herpes simplex virus vector, the composition could be administered in an area where synaptic terminals are located so that the virus can be taken up into the terminals and transported in a retrograde manner up the axon into the axonal cell bodies via retrograde axonal transport. The pharmaceutical composition is typically administered to the brain to by stereotaxic inoculation. When the pharmaceutical composition is administered to the eye, sub-retinal injection is typically the technique used.
When the polynucleotide of the invention is delivered to cells by a viral vector, the amount of virus administered is in the range of from 104 to 10g pfu, preferably from 105 to 10' pfu, more preferably about 106 pfu for herpes viral vectors and from 106 to I Olo i 5 pfu, preferably from 107 to 1 O9 pfu, more preferably about 108 pfu for adenoviral vectors.
When injected, typically 1-2 pl of virus in a pharmaceutically acceptable suitable carrier or diluent is administered. When the polynucleotide of the invention is administered as a naked nucleic acid, the amount of nucleic acid administered is typically in the range of from 1 pg to 10 mg.
2 o Where the polypeptide of the invention is under the control of an inducible promoter, it may only be necessary to induce gene expression for the duration of the treatment. Once the condition has been treated, the inducer is removed and expression of the polypeptide of the invention ceases. This will clearly have clinical advantages. Such a system may, for example, involve administering the antibiotic tetracycline, to activate 2 5 gene expression via its effect on the tet repressor/VP 16 fusion protein.
The use of tissue-specific promoters will be of assistance in the treatment of disease using the polypeptides, polynucleotide and vectors of the invention.
For example, several neurological disorders are due to aberrant expression of particular gene products in only a small subset of cells. It will be advantageous to be able express therapeutic 3 o genes in only the relevant affected cell types, especially where such genes are toxic when expressed in other cell types. Examples of neuronal sub-types which may be targeted specifically include neurons of the peripheral nervous system, for example sensory neurones, motor neurons, autonomic neurons such as sympathetic neurons and parasympathetic neurons, and neurons of the central nervous system, for example motor neurons or sensory neurons.
The routes of administration and dosages described are intended only as a guide since a skilled practitioner will be able to determine readily the optimum route of administration and dosage for any particular patient and condition.
The invention will be described with reference to the following Examples which are intended to be illustrative only and not limiting. The Examples refer to the Figures.
Referring to the Figures in more details:

Figure 1 Brn-3a expression rescues ND7 cells from apoptotic programmed cell death following serum removal.
a) Cell survival in cell lines over expressing Brn-3a (filled squares) or Bm-3b (open circles) maintained in serum free media containing 1 pM RA for 72 hrs, compared to the i s values in ND7 cells transfected with pJ5 vector alone (open squares).
b) Relative amounts of DNA fragmentation within cells expressing either pJ5 vector alone (open squares), Brn-3a (filled squares) or Brn-3b (open circles) maintained in serum free media containing 1 p.M RA for 24, 48 and 72 hrs.
c) TUNEL positive nuclei as a proportion of the total number ND7 cells expressing 2 o either empty pJ5 vector alone or Brn-3a in the absence (stippled bars) or presence (filled bars) of dexamethasone, when maintained in serum free media containing 1 p,M
RA for 48 hrs.
Figure 2 Protection of ND7 cells requires the presence of an N-terminal activation 2s domain within Brn-3a.
a) Schematic representation of the constructs used in this study. Constructs were subcloned into pJ5 expression vector for the generation of stable cell lines, or the pJ4 (Morgenstern and Land, 1990) expression vector for transient expression studies. The chimeric constructs (C1, C2, C3 and C4) were not subcloned into pJS.
3o b) Cell stn"vival in cell lines over expressing long form Brn-3a (filled squares), the short form of Brn-3a (open circles), or the isolated POU domain of Brn-3a (filled circles) when maintained in serum free media containing 1 ~M RA for 24, 48 and 72 hrs and following induction of the MMTV promoter with dexamethasone compared to the value in ND7 cells transfected with pJ5 vector (open squares).
Figure 3 Bcl-2 protein expression is regulated by Brn-3a in ND7 cells.
a) Western blot analysis of Bcl-2 (top panel) and Bad {middle panel) protein s expression in extracts from cell Lines over expressing the indicated construct when maintained in full serum media in the absence (-) or presence (+) of dexamethasone. Equal loading of samples was confirmed by detection of pGp9.5 protein levels (lower panel).
b) Bcl-2 protein expression in cell lines expressing the indicated constructs compared to that in ND7 cells transfected with vector alone (pJ5) maintained in the absence (stippled 1 o boxes) or presence (filled boxes) of dexamethasone.
Figure 4 The human Bcl-2 promoter is regulated by the N-terminal activation domain of the Brn-3a transcription factor.
a) Schematic representation of the 5' end of the human Bcl-2 gene indicating the two ~ s promoter regions (P 1 and P2). ORF indicates the start of the open reading frame; hatched regions indicate introns; x indicates potential Brn-3 binding sites.
b, c) Results of the reporter gene assay following the co-transfection into ND7 cells (filled boxes) or BHK cells {stippled boxes) of the indicated plasmids with (b) P1, (c) P2 Bcl-2 promoter constructs. C1, C2, C3 and C4 indicate the chimeric constructs of Brn-3a 2o and Brn-3b drawn schematically in Fig 2a.
Figure 5 Deletion constructs of P 1 and P2 Bcl-2 promoters identify regions necessary for activation of reporter constructs by Brn-3a.
a) Results of luciferase assays following the co-transfection of the long form of Brn-3a 2 s with the indicated deletion constructs of the human P 1 Bcl-2 promoter identify a 113bp fragtnent {-1528 to -1416) necessary for activation.
b) Results of luciferase assays following the co-tnmsfection of the long form of Brn-3a with the indicated deletion constructs of the human P2 Bcl-2 promoter regions identify a 559 by region (-746 to -178) required for activation. Note the 8-fold increase in activation s 0 of the P2 region following deletion of the sequence between -3933 and -1793 which includes the P 1 region. Stippled boxes are the appropriate vector control transfections for each deletion construct.

Figure G Identification of a motif within the humor Bcl-2 promoter region that is bound by Brn-3a and is sufficient for activation of a heterologous promoter by Brn-3a.
a) Chloramphenical acetyltransferase (CAT) assay of the ability of the indicated Brn-3 factors to transactivate a heterologous promoter containing a 173 by BgIIUNsiI
fragment s from the human P2 Bcl-2 promoter region (-744 to -571).
b) Results of a CAT assay to determine the ability of the indicated Bm-3 factors to transctivate a heterologous promoter containing the minimal CATCAATCTTC
motif contained within the BgIIIINsM fragment and the OligoP2 {-594 to -584).
io Figure 7 Brn-3a over expression protects (a) neonatal dorsal root ganglions and (b) neonatal trigeminal neurons from apoptosis induced by withdrawal of nerve growth factor.
The bars indicate the number of surviving successfully transfected neurons (as determined by staining for the presence of the co-transfected b-galactosidase expressing plasmid). Stippled bars indicate the results in cultures maintained in the presence of NGF
and the solid bars in cultures from which NGF was withdrawn. Cells were either injected with parental expression vector or the Brn-3a expression vector as shown.
Figure 8 Survival of trigeminal ganglion neurons obtained from the indicated stage of embryonic development, transfected with either empty expression vector (solid line) or 2o Brn-3a expression vector (dotted line) and then cultured in the presence (panel a) or absence (panel b) of NGF. Values are the mean of at least three independent experiments whose standard deviation is shown by the bars.
Figure 9 Survival of trigeminal ganglion neurons obtained from the indicated stage 2 5 of embryonic development, transfected with empty expression vector (solid line) or the anti-sense Brn-3a vector (dotted line) and cultured in the presence of NGF.
Values are the mean of at least three independent experiments whose standard deviation is shown by the bars.

WO 99/05272 pCT/GB98l02228 ~'Y A MZ.11.Ti C
Materials and Methods Unless indicated otherwise, the methods used are standard biochemical techniques. Examples of suitable general methodology textbooks include Sambrook et al., Molecular Cloning, A Laboratory Manual (1989) and Ausubel et al., Current Protocols in Molecular Biology (1995), John Wiley & Sons, Inc.
to DNA ladder assay Cells were grown on 5 cm tissue culture dishes (Nunc, Roskilde, Denmark).
After treatment, the cells were harvested, washed once with ice-cold PBS, resuspended in 250 ml of lysis buffer (10 mM Tris-HCl pH 7.6, 20 mM EDTA pH 8.0, 0.5% v/v Triton X-100) and 15 the samples were left at room temperature for 15 min. After centrifugation at 16,000 g for 5 rnin, the supernatant was transferred to another eppendorf tube and sequential extractions were carried out. The samples were extracted once with equal volume of phenol, once with phenol-chloroform ( 1:1 ) and once with chloroform-isoamylalcohol (24:1 ). DNA
was precipitated with 0. 1 volumes of 3 M sodium acetate pH 4.8 and 2.5 volumes of ethanol at -20 20°C overnight. The DNA was then pelleted at 16,000 g for 30 min the next day. After washing once with 70% ethanol, the samples were digested with 0.1 p.g of RNAase A at 37°C for 30 min before loading onto 1.5% agarose gels and the DNA was visualized by ethidium bromide staining.
2 5 TUNEL assay Measurement of DNA fragmentation by the terminal-deoxynucleotidyl-transferase (TnT) - mediated dUTP-biotin nick end labelling assay (TUNEL) was carried out using the Apop Tag detection kit (Oncor, Gaithersburg, MD) according to the manufacturer's instructions. Briefly, residues of digoxigenin-nucleotides are added to the 3'-OH end of 3 o DNA fragments by terminal deoxynucleotidyl transferase and the anti-digoxigenin antibody peroxidase conjugate is used to stain the apoptotic DNA fragments.

wo 99rosz~ rcr~cs9srozzzs Cxample 1 - Iirn-3a rescues ND7 cells from apoptosis We have used the ND7 neuronal cell line (Wood et al., 1990) as a model system to identify genes whose protein products could pmtect neuronal cells from apoptosis.
These cells were originally isolated by the imrnortalisation of rat dorsal root ganglion s (DRG) neurons and can be grown in large amounts in culture. We have previously reported the construction and characterisation of cell lines derived from the ND7 sensory neuronal cell line that over express high levels of the various members of the Brn-3 family of transcription factors under the control of the glucocorticoid-inducible MMTV
promoter (Smith et al., 1997a&b). Upon serum removal parental ND7 cells undergo 1 o either apoptotic programmed cell death (PCD) or differentiation to a non-dividing phenotype bearing neuritic processes, whilst retinoic acid (RA) enhances the degree of apoptosis during the differentiation event (Howard et al., 1993).
Following the transfer of the stable cell lines containing the pJ5 vector (Morgenstern and Land, 1990) with no insert to serum free media containing 1 p.M
~ s dexarrlethasone to induce the MMTV promoter, a proportion of cells ceased to proliferate and began to extend processes, in agreement with previous studies. The degree of cell death in these control cells was assayed by trypan blue exclusion and found to be similar to that in parental ND7 cells at all timepoints. The addition of 1 pM all-trans RA to the differentiated cultures resulted in a further decrease in the number of viable cells at all 2 o timepoints. These data demonstrate that the addition of dexamethasone has no significant effect on the proportion of viable cells when compared to the effects observed in parental ND7 cells under the same experimental conditions. These similarities were observed in all vector-alone control cell lines that were studied. However, significant increases (24hr p<0.05; 48hr p<0.005; 72hr p<0.05) in the number of viable cells, were observed in the 2s three independent cell lines stably overexpressing high levels of full-length Brn-3a (Brn-3aL) following the induction of the MMTV promoter upon the addition of 1 p.M
dexamethasone to the RA-containing serum-free media (Figure la; Table I, Brn-3aL).
Similar protection was afforded by over expression of Brn-3a in serum free media that was not supplemented with RA .

TABLE I. Over expression of Brn-3a, but not Brn-3b or Brn-3c, rescues ND7 cell following serum removal.
Cell survival (Number of viable cells as %
of original cell population) ~

24 hours 48 hours 72 hours Dex - Dex + Dex - Dex + Dex - Dex +

pJ5 6016 6315 4915 4118 41f7 4419 Brn-3aL 63110 78t6* 6118 80f9** 54111 66~8*

Brn-3b ?i~12 6516 40f9 43+5 43112 3816 Brn-3aS 5511 Slt7 519 45112 3616 4018 Brn-3aP 61f4 SSf9 456 40f6 4711 4218 Brn-3aI 7115 7018 5719 8215** 527 6914*_ Brn-3bV 674 6516 416 447 42110 38+6 ~ Cell survival 24, 48 and 72 hours following transfer to serum free media containing 1 wM
retinoic acid determined by trypan blue exclusion. Values are means + standard deviation of the mean determined in duplicate for three independent cell lines expressing each construct. L= long form, S=short form, P=isolated POU domain, I=Isoleucine mutant, V=valine mutant.
l o * Statistically significant increase from appropriate vector control (p<0.05) ** Statistically signiftcant increase from appropriate vector control (p<0.005) Thus as transfer of ND7 cells to serum free media containing RA is known to induce apoptotic PCD, these data show that elevated levels of Brn-3a are capable of rescuing ND7 cells from a fate of apoptotic PCD. Such a reduction in the number of apoptotic cells was confirmed by flow cytometric analysis of PI/FITC stained cells which identified an apoptotic population with less than 2N DNA content in differentiated control ND7 cells (empty vector alone) which was reduced following the induction of Brrt-3a expression in the three Brn-3a over expressing lines. No significant alteration in the 2o number of viable cells or in the degree of apoptosis was observed in all cell lines over WO ~~~~ PCTIGB98/022Z8 expressing Brn-3b (Figure 1 a Table I}.
To confirm and extend these observations, we utilised a number of techniques to assay the degree of nucleosomal fragmentation of genomic DNA. The over expression of Bm-3a resulted in a decrease in the proportion of fragmented DNA within the cell s populations as determined by both the colormetric DNA fragmentation assay of Sellins and Cohen ( 1987), as well as the degree of nucleosomal laddering following agarose gel electrophoresis of genomic DNA. No significant alteration in the degree of chromatin fragmentation was observed in cell lines over expressing Bm-3a.
These observations were extended by the labelling of the cultured cells by the io TUNEL technique which utilises the labelling of free 3' DNA ends by terminal deoxynucleotide transferase to visualise the DNA fragments generated by the characteristic endonucleolytic cleavage which occurs during apoptosis. As shown in Figures 1 c and 1 d, the over expression of Brn-3a resulted in a 3 fold decrease in the number of TUNEL positive cells as compared to the cell line over expressing the vector 15 alone, at 24 hours (45t%, p<p.005), 48 hours (3516%, p<0.001) and 72 hours following transfer to serum free media containing RA (3718%, p<0.001). As expected a high proportion of Brn-3a expressing which survived in serum free media containing RA were observed to be process bearing.
Taken together these findings indicate that stable over expression of Brn-3a can 2o protect ND7 cells from an apoptotic fate following one type of differentiation stimulus, and that a proportion of rescued cells are able to differentiate normally. Our previous experiments demonstrate that the ability of Brn-3a to activate its target promoters is dependent on the presence of two activation domains which are absent in Brn-3b. Thus the activation of the tk-Oct test promoter {containing a binding site for the Brn-3 factors 2 s upstream of the herpes simplex virus thymidine kinase promoter) requires only the DNA
binding POU domain which also acts as an activation domain (Moms et al., 1994). In contrast, this domain has no effect on the a-intemexin promoter, which requires a distinct domain at the N-terminus of Bm-3a for promoter activation (Budhram-Mahadeo et al., 1995). Interestingly, both the maximal activation of the SNAP-25 promoter and the 3o ability of Brn-3a to induce process outgrowth to maximal effect requires the presence of both domains, although the POU domain alone is able to confer a less than maximal response (Morris et al., 1997; Smith et al., 1997a).
To test the effects of each of these domains on the ability of Brn-3a to rescue ND7 cells, we prepared pJ5-based stable cell lines overexpressing the isolated POU
domain of Brn-3a; or a naturally occuring short form of Brn-3a (Theil et ul., 1993) which lacks the N-terminal activation domain (Smith et al., 1997a). When these cell lines were analysed for their ability to rescue ND7 cells from apoptotic PCD, neither the Brn-3a POU domain s alone or the short form of Brn-3a were able to confer the protection afforded by full-length Brn-3a (Table I and Figure 2b). Hence the ability of Brn-3a to protect ND7 cells from serum removal induced apoptosis is dependent upon the presence of the N-terminal activation domain that is present in full-length Brn-3a.
We have shown previously that a difference at position 22 in the POU
to homeodomains of Brn-3a and Bm-3b plays a critical role in the opposite effects of these two isoforms on some target promoters and upon neurite outgrowth. In particular, a construct in which the valine at position 22 of the homeodomain of Brn-3a is replaced with , isoleucine (Brn-3aI construct) is no longer able to activate the tk-Oct test promoter in cotransfection assays (Dawson et al., 1996), and is much less able to induce process i5 outgrowth when overexpressed in stable ND7 cell lines (Smith et al., 1997a).
To further extend the observation that the N-terminal domain of Brn-3a is apparently critical for Brn-3a to the rescue ND7 cells from apoptosis, we constructed stable cell lines capable of overexpressing these mutant forms of Brn-3a (Brn-3aI) and Brn-3b (Brn-3bV). The Brn-3aI cell line, in which the expressed protein contains the 2o N-terminus of Brn-3a but the functional POU domain of Brn-3b, maintained the ability to rescue ND7 cells when assayed by all criteria described above (Table I). This contrasts with the inability of this construct to induce neurite outgrowth due to the lack of a functional Brn-3a POU domain (Smith et al., 1997a). Conversely, the overexpression of the Brn-3bV construct which contains a functional Brn-3a POU domain but in conjuction 2s with the N-terminus of Brn-3b (Brn-3bV), was unable to rescue ND7 cells (Table I).
Example 3 A. Brn-3a enhances Bci-2 protein expression in ND7 cells To explore the possible mechanisms by which the protection against apoptosis 3o could be conferred by Brn-3a, Western blot analysis was performed on protein extracts from the various cell lines following the observation that Bcl-2 protein level increased approximately four-fold upon differentiation of parental ND7 cells. Incubation with a Bcl-2 specific antibody revealed a sixteen-fold increase in Bcl-2 protein levels in Brn-3a *rB

(long form) over expressing cell lines compared to those expressing vector alone (Figure 3a top panel and Figure 3b). No significant increase in Bcl-2 protein was observed in extracts from cells induced to over express Bm-3b (Figure 3a and 3b). No significant changes in Bcl-2 protein levels were observed in vector control cells indicating that the addition of dexamethasone to the media does not regulate Bcl-2 in ND7 cells (Figure 3a top panel).
Investigation of protein extracts from the cell lines overexpressing the mutagenised forms of Brn-3a (Brn-3aI) and Brn-3b (Brn-3bV) revealed that mutation at position 22 did not significantly ai~ect the ability of Brn-3a to induce Bcl-2 protein levels, whilst the converse mutation of Brn-3b did not enable this factor to alter Bcl-2 protein levels .
to Together these data suggest that the activation domain of Brn-3a responsible for regulation of the Bcl-2 gene is likely to be external to the POU domain.
This hypothesis was subsequently confirmed upon analysis of protein extracts from cell lines overexpressing either the isolated Brn-3a POU domain or the naturally occurring short form of Brn-3a. Stable overexpression of either of these two constructs did not i s signif cantly alter Bcl-2 protein levels , thus demonstrating that the regulation of Bcl-2 protein expression by Brn-3a is dependent on the N-terminal activation domain present in Brn-3a (long form) paralleling the requirement for this domain in conferring protection from apoptosis in these cells .
2 o B. Brn-3a does not regulate other members of the Bcl-2 family No significant alterations in the level of Bad or Bax protein expression was observed in any of the cell lines, whilst neither isoform of Bcl-x (Bcl-xL or Bcl-xs) was expressed at detectable levels in these cells .
25 C. Regulation of the Bcl-2 promoter by Brn-3 The 5' flanking sequence of the human Bcl-2 gene contains two distinct promoters (Pl and P2) that are r~uired for initiation of transcription (Figure 4a).
Although it is not known which of these two promoter regions is utilised in cells of neuronal origin, studies have demonstrated that in other cell types in which Bcl-2 promoter activity has been s o characterised (predominately cells of haemopoetic lineage) transcription is predominately initiated from the Pl region. Bcl-2 transcription in the ND7 neuronal cell line used in this study is predominately initiated from within the P2 promoter region in both the undifferentiated and differentiated state (unpublished data).

To examine the regulation of the Bcl-2 promoter by the Brn-3 family members, plasmid constructs containing either the P 1 or P2 promoters driving the luciferase reporter gene (Figure 4a} (Chen and Boxer, 1995) were cotransfected into parental ND7 cells with constitutive expression vectors containing either Brn-3a (long form), Brn-3a (short form) or s Brn-3b.
in the parental ND7 cell line, both promoter constructs (P1 and P2) were significantly activated by the long form of Brn-3a (Figures 4b and c; p<0.01 in all cases) although the P2 construct was activated by Brn-3a to a much greater degree that observed with the P1 construct. The short form of Brn-3a also activated the P1 reporter construct but to only to approximately one fifth of the activity conferred by Bm-3a long (Figure 4b;
p<0.05). Both Brn-3b and the short form of Brn-3a had no significant effect on the P2 promoter construct, although Brn-3b did significantly repress the basal activity of the P 1 promoter (Figure 4b: p<0.01 ).
By contrast in BHK cell cotransfection experiments no significant effect on the i 5 activity of the P 1 promoter reporter gene construct was observed following cotransfection with Brn-3a or Brn-3b (Figure 4b). A small but significant increase in the P2 (250f21%, p<0.01 ) reporter gene construct was however observed after cotransfection with Brn-3a, but these effects were significantly less than those observed in ND7 experiments (data not shown, p<0,001 and p<0.005, respectively). No effects were observed following 2o cotransfection of Brn-3b with either promoter construct into BHK cells (Figure 4b and c).
Therefore, these data demonstrate that the Bcl-2 promoters are activated much more (approximately 10 fold higher) in ND7 cells compared to BHK cells, suggesting a neuronal specific effect. Taken together with the data from ND7 cotransfections, these data also suggest a much stronger activation potential of Brn-3a for the construct containing the P2 2s promoter region and the sequences immediately 5' to this region in cells of neuronal origin.
Importantly, no significant differences between the basal activities of these reporter constructs in ND7 and BHK cells was observed.
The specificity of these effects to the neuronally expressed Bm-3 family of POU
factors was confirmed by co-transfection experiments using the Bcl-2 promoter construct in so combination with constructs expressing Oct-1, Oct-2.1, Oct-2.4 and Oct-2.5.. No activation or repression of Bcl-2 promoter activity was observed upon co-transfection of these Type II
POU factors into either ND7 or BHK cells .

WO 991as272 PCT/GB98/OZ228 U. The 5' and 3' Bcl-2 promoters arc regulated by the N-terminal activation domain of the long form of Brn-3a To investigate the difference in the levels of activation of the reporter gene constructs by the long and short forms of Brn-3a, the Bcl-2 promoter constructs were co-y transfected with expression plasmids containing the Brn-3a POU domain alone, or chimeric Bm-3 constructs generated by the substitution of regions of Brn-3a with the corresponding regions of Brn-3b (Figure 2a).
The isolated POU domain of Brn-3a was not sufficient to confer regulation on Bcl-2 promoter activity (Figures 4b and c) extending the data obtained from the homeodomain o position 22 mutants. Moreover, using previously described chimeric constructs containing various combinations of domains of Brn-3a and Brn-3b (Figure 2a) we wished to further characterise the regions of Bm-3a necessary for the activation of the Bcl-2 promoter.
Replacement of either the POU domain region (chimera 1), the region immediately 5' to the POU domain {chimera 2), or both these regions (chimera 3) of Brn-3a with the i5 corresponding region of Brn-3b but retaining the N-terminal domain of Bm-3a did not significantly alter the ability of these chimeric constructs to activate the reporter constructs in the manner of Brn-3a (long form) (Figures 4b and c). In contrast, a chimera containing the POU domain of Brn-3a but with the N-terminal region of Brn-3b (chimera 4) was not capable of activation (Figures 4b and c). Taken together these data extend the previous 20 observations and demonstrate that the N-terminal activation domain, and not the POU
activation domain; is necessary for activation of the BcI-2 promoter, although the POU
domain is necessary for DNA binding. This result parallels the observation that th.e N-terminal domain is necessary for activation of endogenous Bcl-2 expression as well as protection of ND7 cells from apoptosis.
E. A potential Brn-3a binding site in Bcl-2 is sufficient for transactivation To identify the sequence elements within the P 1 and P2 regions necessary for transctivation by Bm-3a, deletion constructs of the two Bcl-2 promoters were cloned upstream of the luciferase reporter gene and were cotransfected into parental ND7 cells so together with the Bm-3a expression plasmid. Deletion of the P1 promoter revealed a 113bp fragment (-I4I2 to -1525) necessary for transactivation by Brn-3a (Figure Sa), and which contained a repeat element CCTCTTACTTC (SEQ ID. No. 5) similar to the CTTCNNNCTTC (SEQ ID. No. 6) motif within the intemexin promoter that has previously _29_ been shown to bind Brn-3a and Brn-3b (Budhram-Mahadeo et cal., 1995), and which is only activated via an N-terminal activation domain present in the long form of Brn-3a.
Investigation of the region containing the P2 Bcl-2 promoter revealed a 569 by region (-746 to -178) immediately 5' to the region containing the intron and NItE (Young and Korsemeyer, 1993), that was necessary for transactivation by Brn-3a (Figure 5a). This region contains two repeat elements, CTTCTGCTTC (SEQ ID. No. 7) and CATCAATCTTC (SEQ ID. No. 8) similar in sequence to the intemexin CTTCNNNCTTC
(SEQ ID. No. 6) motif identified in a-internexin. A 173 by BgIIIINsr'I
fragment containing this region was excised and subcloned into the chloroamphenicol acetyltransferase reporter o gene vector pBL2CAT, and subsequently co-transfected into parental ND7 cells with the Brn-3 expression plasmids. Co-transfection with Brn-3a and Brn-3aI resulted in significant elevation of CAT reporter gene activity (both p<p,05), whilst Brn-3b and Brn-3bV did not result in any significant alteration in reporter gene activity (Figure 6a).
i s F. Brn-3a binds to elements within the Pl and P2 Bcl-2 promoters To confirm that the Brn-3 factors were capable of binding these sequence elements, the synthetic oligonucleotides containing the sequence CCTCTTACTTC (SEQ ID.
No. 5) from the P 1 promoter (OligoP 1 ) and the sequence CATCAATCTTC (SEQ ID. No. 8) from the P2 promoter (OligoP2) were used for electromobility shift assay.
2 o Both double stranded oligonucleotides (OligoP 1 and OligoP2) bound to in vitro translated Brn-3a although the affinity of Brn-3a for OligoP2 was approximately 10-fold stronger than for P 1 as determined by competition with unlabelled oligo .
Specificity of binding was confirmed by competition for binding sites in presence of an excess of unlabelled oligonucleotide. Using individual oligonucleotides as single stranded probes 25 revealed that in both cases Brn-3a bound to the antisense sequence with much greater affinity that to the sense strand . Such an observation is consistent with our previous studies of the a-intemexin promoter where we reported that Brn-3a similarly bound the antisense strand containing the CTTCNNNCTTC (SEQ ID. No. 6) motif with greater affinity that it bound the corresponding sense strand (Budhram-Mahadeo et al., 1995).
3o To determine if these elements alone were sufficient to confer Brn-3 mediated responsiveness, both oligonucleotides were cloned into the pBL2CAT reporter gene vector.
The elements contained in these oligonucleotides were thus 5'-CCTCTTACTTC-3' (-to -1503) of P1 (OligoPl) (SEQ ID. No. 5), and 5'-CATCAATCTTC-3' (-584 to -594) of WO 99/05272 PCT/GB98~2228 the region containing P2 (OligoP2) (SEQ ID. No. 8). Analysis of extracts from cells co-transfected with these constructs together with Brn-3 expression vectors demonstrated that the element contained within OligoP2 was sufr'icient to confer responsiveness to Brn-3a (Figure 6b) although the degree of activation by Hrn-3a of this construct was considerably less than previously observed in the experiments using either the full length promoter (compare with Figure 4c) or the isolated 173bp BgIII/Nsil fragment (compare with Figure 6a). The isolated element contained within OligoPl was not sufficient to confer Brn-3a responsiveness .
io G. The box gene promoter is not regulated by Brn-3 To determine whether the transctivation of the Bcl-2 promoter by Brn-3a was a feature of other Bcl-2 related genes, a plasmid containing -68? to -318bp of the human box promoter region cloned upstream of the CAT reporter gene (clone TM-668;
Miyashita and Reed, 1995) was co-transfected into ND7 and BHK cells together with the various Brn-3 i s expression plasmids. No significant elevation or repression of CAT
reporter gene expression levels was observed in all experiments .
Example 4 - The long form of Brn-3a rescues primary DRG and cerebellar neurons from apoptosis 2o To extend the in viva relevance of these findings Brn-3 expression constructs were microinjected into primary cultured neonatal DRG neurons together with a lacZ
expressing marker plasmid, and protection from NGF withdrawal-induced apoptosis assessed, and effects on cultured cerebellar neurons following glutamate induced apoptosis measured.
These experiments showed a similar and highly statistically significant reduction in the 25 numbers of cells undergoing apoptosis following Brn-3a expression which was not shown after expression of Brn-3b (see below).
Materials and Methods DRGs were dissected from newborn Wistar rat pups at postnatal day 1 (P 1 ).
3o Following the removal of connective tissue sheaths, cells were dissociated in collagenase (0.3%) and subsequently seeded onto poly-ornithinellaminin coated glass coverslips at a final density of 200-250 neurons per coverslip. Cells were cultured in defined medium (Davies, 1995) supplemented with recombinant NGF at a final concentration of 20 ng/ml.

WO 99/OSZ72 PCTIGB98102?.28 The following day, the number of neurons present on each coverslip was determined by standard microscopic means. Neurons were microinjected with 100 ng/cell of pCi (Promega) expression vector containing marine long form Brn-3a cloned downstream of the constitutive cytomegalovirus gene promoter. Control neurons were injected with 100 nglcell of empty pCi expression vector. Microinjections were made into the nuclei of cells, and all neurons on the coverslips were injected.
Cultures were incubated for a further 24 hours before media was replaced with fresh media that did not contain NGF. In order to determine the amount of cell death in cultures containing NGF, the media in duplicate coverslips was replaced with media supplemented 1 o with NGF. The number of neurons on each coverslip was determined 24 hours following NGF withdrawal.
Cell survival was calculated for each sample as the number of neurons post-injection as a proportion of the pre-injection number.
Results To investigate the potential role for Brn-3a in the regulation of the survival of developing neurons we analysed the effect of over expression of this factor in primary cultures of NGF-dependent postnatal DRG neurons. Over expression of Brn-3a enhanced the survival of DRG neurons deprived of NGF (Figure 7a, Table II). Thus the long form of 2o Bm-3a can promote the survival of NGF deprived DRG neurons and that this effect is dominant to that of NGF.
Table II. Brn-3a overexpression protects neonatal dorsal mot ganglion neurons from apoptosis induced by withdrawal of nerve growth factor.
Injected Construct ~ Total Number of Cells +NGF -NGF

Vector 220 126 Brn3a 236 220 Similar results were obtained in primary cultures of sensory neurons obtained from neonatal rat trigeminal ganglia cultured and treated in an identical manner (Fig 7b, Table III). This population of neurons are also dependent on NGF for survival in vitro.

Table III. Brn-3a over expression protects neonatal trigeminal ganglion neurons from apoptosis induced by withdrawal of nerve growth factor.
.~.~.
Injected Construct Total Number of Cells - --_ +NGF -NGF

Vector 125 40 Bra 125 95 Example 5 - Expression of Brn-3a in DRG neurons using a disabled herpes simplex viral vector.
Materials and Methods to Culture of Primary Neurons Dorsal root, trigeminal and superior cervical ganglia were dissected from newborn Sprague Dawley rat pups at postnatal day 1 (P 1 ) or staged C57 mouse embryos where the day of finding the vaginal plug was designated embryonic day e0.5. Following the removal s of connective tissue sheaths, ganglia were incubated in trypsin (0.1%
(Worthington) in calcium and magnesium-free Earles Balanced Salt Solution). Ganglia were then washed twice in PBS, dissociated and plated onto sterile glass coverslips precoated with polyornithine (0.5 mglml) and laminin (20 pg/ml) at a final density of approximately 200 neurons per coverslip. Cells were cultured in defined medium supplemented with 2 o recombinant nerve growth factor (NGF; Gibco) at a final concentration of 20 ng/ml.
The following day, 1 pg of pCi expression vector containing the marine long form of Brn-3a cloned downstream of the constitutive cytomegalovirus {CMV) gene promoter (pCi3A) was introduced into cultured cells by liposome-mediated transfection.
Control cultures were similarly transfected with 1 ~g of empty pCi expression vector (pCi).
25 Transfected cells were incubated for 24 hours following transfection and media was then replaced with fresh medium with or without the addition of NGF. To determine efficiency of transfection and to identify individual transfected neurons, cultures were co-transfected with 1 pg of plasmid encoding the lacZ gene under the control of the CMV
promoter (CMV-LacZ). Survival of transfected cells (as visualized by ~i-galactosidase staining) was 3o assessed twenty four hours after the transfer to medium with or without NGF. In parallel experiments 100 ng of plasmid DNA (pCi or pCi3A together with CMV-LacZ) was introduced into nuclei of neurons by microinjection.
Virus Construction and Growth s Plasmid pR20.5 consists of an RSV/LacZIpA and a CMV/GFPIpA cassette in opposite (back-to-back) orientations separated by a central region derived from the HSV
genome (nts 118,866-120,219) which allows expression of both the RVS and CMV
driven genes during HSV latency. These sequences can be excised from the pGEMS
(Promega) plasmid backbone with SrfT since an oligonucleotide containing a SrfT site was to inserted on either side of this cassette. The RSV promoter was excised from pRc/RSV
(invitrogen), IacZIpA from pCH 110 (Pharmacia), CMV/pA from pcDNA3 (Invitrogen) and GFP from pEGFP-N1 (Clontech) for the construction of plasmid pR20.5.
The RSV/LacZIpA and CMV/GFP/pA expression cassette was excised from pR20.5 by digestion with Srfl and sub-cloned into the unique NsiI site of a shuttle vector i5 containing herpes simplex virus 1 (HSV-1) UL43 gene sequences (Coffin et al., 1996) so that the cassette was flanked by UL43 gene sequences. This gave plasmid pR20.5/LJL43.
The full length Brn-3a cDNA was cloned into the BamHl site of plasmid pR20.5/UL43, downstream of the Rous sarcoma virus (RSV) promoter, and in reverse orientation to the cDNA encoding green fluorescent protein {GrP) cloned under the control of the CMV
2o promoter. The resulting pR20.5/Brn-3a/UL43 shuttle vector was then co-transfected into BHK cells together with HSV-1 strain 1764 DNA which contains an inactivating insertion in the Vmw65 gene as well as deletion of both copies of the ICP34.5 gene (Coffin et al., 1996b). Recombinant virus was subsequently plaque purified on the basis of the visualisation of GFP under ultraviolet conditions. Western blot analysis was performed to 2 s confirm that high levels of Brn-3a protein were produced in infected cultures before a high titre stock was grown. Control virus containing the bacterial lacZ gene under the RSV
promoter (that is, containing pR20.5/IacZ/UL43) was similarly generated but without the Brn-3a cloning step.
Trigeminal ganglion neurons were isolated and maintained in cultures as described 3o above on glass coverslips at a density of approximately 200 neurons per coverslip. Cultures were infected in duplicate with approximately 1 x 105 plaque forming units (pfu)/coverslip of Brn-3a or control virus for 60 mins, washed and then maintained in medium supplemented with NGF for 24 hours. Efficiency of viral infection was determined by visualisation of GFP before media was replaced with fresh media with or without the addition of NGF.
Neuronal cell counts were then performed 24 hours later.
Statistics s Comparisons between medians were performed with the Mann-Whitney test using Minitab for Windows software.
Results To demonstrate that viral vectors directing the over-expression of Brn-3a could be o introduced efficiently into neuronal cells we prepared a disabled herpes simplex virus (HSV) vector expressing both Brn-3a and the green fluorescent reporter protein (GFP).
This vector lacks functional viral genes encoding the Vmw65 transactivator protein and the ICP34.5 neurovirulence factor and we have previously shown that it is able to effectively deliver genes to neuronal cells both in vitro and in vivo without causing significant neuronal cell death.
Cultures of cervical or lumbar DRGs from E16 embryonic animals were infected with this virus or with a control virus expressing only a reporter gene. The effect on survival in the presence or absence of NGF was assessed as before. In these experiments (Table IV) both the cervical and lumbar DRG cultures showed dramatic neuronal losses 2o upon NGF withdrawal. In both cases, the Brn-3a expressing virus was able to produce significant protection against such loss. These data thus demonstrate that the protective effect of Brn-3a can be observed with a virus vector as well as by liposome-mediated delivery of a Brn-3a expression plasmid.
2s Table IV Survival of cultures of E16 lumbar or cervical dorsal root ganglion neurons infected with a disabled herpes simplex virus vector expressing green fluorescent protein (vector) or the same virus expressing Brn-3a and then cultured in the presence or absence of NGF. Values are the mean of at least three independent experiments whose standard deviation is shown.

Lumbar ~ ~ Cervical I
-Vector +NGF 9810 98.510.5 Vector -NGF 25.Sf1.5 38.510.5 Brn 3a +NGF 89.518.5 8318.5 Brn 3a -NGF 71.510.5 8815 Example 6 - Endogenous Brn-3a protects neuronal cells from apoptotic cell death s Materials and Methods Plasmid constructs Full length Brn-3a cDNA expression vectors are described in Smith et al., 1997c, Lakin et al., 1995 and Budhram-Mahadeo et al., 1995. Antisense Brn-3a specific construct was generated by polymerase chain reaction (PCR) using the primers GGATCCGCTGCAG AGCAACCTCTTC (SEQ ID No. 9) and GTCGACGAGCGA
CGGCGACGAGATC (SEQ ID No. 10) where the bold and underlined sequences indicate BainHI and SaII restriction enzyme recognition sites respectively. The 240 base pair PCR
product was ligated into pGEM-T vector (Prornega, UK) and subcloned as a BamHI/SaII
15 fragment into the mammalian expression vector pJ7 (Morgenstern,and Land, 1990b) Results We have shown in the previous examples that over-expression of Brn-3a plays a role in the regulation of the survival of developing neurons. To determine whether 2o endogenous Brn-3a expression also plays a role in the survival of these neurons, an anti-sense approach was used. Thus, a specific anti-sense construct was generated in which a 240 base pair region derived from the N-terminus of Brn-3a which cannot cross-hybridize to either Brn-3b or Brn-3c was expressed in an anti-sense orientation under the control of the CMV promoter. We have previously used a similar approach to successfully reduce 25 the level of Brn-3a in an immortalised neuronal cell line (Lakin et al., 1995).
Trigeminal ganglion neurons obtained from rat pups at post natal day one were cultured for 24 hours in medium supplemented with NGF and plasmid DNA was then introduced by liposome-mediated transfection. Parallel samples of cells were transfected WO 49/052?2 PCT/G898I02228 with either (i} empty expression vector lacking any insert. (ii) the same expression vector containing full length cDNA for Brn-3a cloned downstream of the constitutive cytomegalovirus gene promoter or (iii) the same expression vector containing the 240 by anti-sense construct derived from the N-terminus of Brn-3a. Each transfection also included a /3-galactosidase expression vector allowing successfully transfected cells to be visualized, by staining for ~i-galactosidase. Typical transfection efficiency was observed to be between 60-70%. The cell survival was then calculated for each sample on the basis of the number of surviving transfected neurons in each case.
In these experiments, as before, a clear enhancement of survival in the cells to transfected with Brn-3a was observed compared to those transfected with vector even in the presence of NGF (Tables V and VI). However, importantly, both trigeminal (Table V) and DRG (Table VI) neurons showed significantly reduced survival when transfected with the Brn-3a anti-sense construct compared to the transfection with empty expression vector.
This reduced survival was observed both in the presence or absence of NGF, indicating that i5 expression of Brn-3a is important for survival under both these conditions (p<0.05 when survival of cells transfected with vector is compared to that of cells transfected with the Brn-3a anti-sense plasmid). Interestingly, in this case, the higher survival of DRG neurons in the absence of NGF was paralleled by a greater reduction in their survival when transfected with the Brn-3a anti-sense construct (compare Tables V and VI).
Table V. Survival of cultures of post-natal trigeminal ganglion neurons, transfected with empty expression vector, Brn-3a expression vector or anti-sense Brn-3a vector and then cultured in the presence or absence of NGF. Values are the mean of at least three independent experiments whose standard deviation is shown.
+NGF
~~ -NGF

Vector ~ 703 27117 Brn 3a 915 7910.5 Bra 3a antisense 35111 1819 These data thus indicate that Brn-3a over expression can enhance the survival of both trigeminal and DRG neurons both in the presence and absence of a specific neurotrophic factor.
s Table VI Survival of cultures of post-natal dorsal root ganglion neumns, transfected with empty expression vector, Brn-3a expression vector or anti-sense Brn-3a vector and then cultured in the presence or absence of NGF. Values are the mean of at least three independent experiments whose standard deviation is shown.
+NGF -NGF

Vector 74.5111.5 475 Brn 3a g4t6 64117 Brn 3a antisense 3717 1513 Example 7 - Over-expression of Brn-3a increases neuronal cell survival at different stages of development.
To extend the studies on the ability of Brn-3a to protect neurons from different stages of development, we carried out similar studies examining the effect of over t s expressing Brn-3a on trigeminal ganglion cultures prepared from different embryonic stages from E11 to E18. In these experiments, Brn-3a over-expression had little effect on survival in the presence of NGF compared to the level of survival observed in cells treated with vector alone at the different stages of development examined, presumably because of the high levels of survival which were observed under these conditions (Figure 20 8a). By contrast, in the absence of NGF, the cultures over expressing Brn-3a showed clearly enhanced survival compared to the cultures treated with vector which was observed at all time points {p<0.05 for comparison of Brn-3a or vector treated cells at all time points tested). This indicates that over-expression of Brn-3a can protect trigeminal ganglion neurons at a number of different stages of embryonic development (Figure 8b).
2s As Brn-3a is expressed in trigeminal ganglia throughout this period of development, we also wish to determine whether anti-sense inhibition of Brn-3a expression would reduce the survival of trigeminal ganglion neurons from different developmental stages. As indicated in Figure 9, anti-sense inhibition of Brn-3a expression led to reduced survival of the trigeminal ganglion neurons in the presence of WO 9910sZ72 PCTIGB98/0222$

NGF when these neurons were derived from the later stakes of embryonic development with highly significant differences in survival being observed between the vector control and the Brn-3a anti-sense treated neurons in cultures prepared from day EI4 onwards. In contrast, much smaller effects were observed at day E 12 and E 13 with no effect at all at s E11.
Hence, the endogenous Brn-3a which is expressed in neurons at all these stages appears to play a more significant survival-promoting role as development proceeds.
This is in agreement with the finding that the trigeminal ganglia of Brn-3a knock out mice appear to be of normal size early in embryonic development and exhibit significant to differences in size from those of wild type animals only later during embryonic development and post-natally.
Discussion We have used the ND7 neuronal cell line as a model system to identify genes whose 1 s protein products could protect neuronal cells from apoptosis. In testing genes which might protect neuronal cells from apoptosis we have examined the Brn-3a and Brn-3b transcription factors which were originally identified in our laboratory. The ND7 cell Iines artifically over-expressing Brn-3b or the short form of Brn-3a showed no difference from control ND7 cells in the extent of apoptosis following transfer to serum free medium with 2 o added retinoic acid indicating that these factors had no protective effect. In contrast the cell lines over-expressing the long form of Brn-3a showed dramatically reduced cell death following such transfer as assayed both by measures of total cell death (the ability to exclude the dye trypan blue) and measures of the degree of apoptosis (the number of cells with less than diploid DNA content, chromatin fragmentation assays and TUNEL
labelling 2 s to detect free ends of partially degraded DNA).
Hence the long form of Brn-3a but not Brn-3b or the short form of Bm-3a can protect ND7 cells against apoptosis. This effect appears to be associated with the ability of the long form of Bm-3a to induce the expression of the Bcl-2 protein. Thus the ND7 cells expressing the long form of Brn-3a over express Bcl-2 approximately fifteen fold 3 o compared to control cells or those expressing the short form of Brn-3a or Brn-3b.
Moreover the bcl-2 gene promoter is activated by the long form of Brn-3a in co-transfection assays. As is the case for the anti-apoptotic effect, such activation is dependent upon the N-terminal domain of the long form since it is not observed with the WO 99!05272 PCT/GB98102228 _39_ short fornl of Brn-3a which lacks this domain. In contrast, both the long and short forms of Brn-3a can activate the promoters of genes such as those encoding the neurofilaments and SNAP-25 which are involved in neurite outgrowth and this activation is dependent upon the C-terminal POU domain of the protein which is common to both forms of the proteins.
s This parallels our finding that the C-terminal domain is essential for inducing neurite outgrowth in ND7 cells and that this effect can thus be induced by both the long and short forms of Brn-3a.
Thus the effects of Bin-3a on protection from apoptosis and stimulation of neurite outgrowth require distinct regions of the protein with the N-terminal domain being required ~ o for protection from cell death whilst the C-terminal POU domain stimulates neurite outgrowth. Interestingly, a single mutation in the POU domain of Brn-3a converting a valine residue to the isoleucine found at the equivalent position in Brn-3b abolishes its ability to stimulate genes involved in neurite outgrowth and prevents it from stimulating such outgrowth. However, as expected, this mutation has no effect on the ability of Brn-3a i 5 to activate Bcl-2 expression or protect cells from programmed cell death since it does not affect the N-terminal region of the protein. It is therefore possible to prepare forms of Brn-3a with all possible combinations of effects on neurite outgrowth and cell death. The naturally occurring long form of Brn-3a stimulates both neurite outgrowth and survival whilst the short form stimulates only neurite outgrowth. Similarly the long form containing 2o the valine to isoleucine mutation will stimulate survival but not neurite outgrowth whilst the short form containing this mutation has no effect on either process.
These forms of Brn-3a thus offer a unique panel of reagents able to stimulate neurite outgrowth and/or neuronal cell survival acting by stimulating the expression of multiple genes involved in each of these processes. Brn-3a may represent a master 25 regulator inducing specific programmes of gene expression required for neuronal cell survival and process outgrowth. The over expression of Brn-3a is therefore likely to be of more value in a therapeutic situation than the over expression of a single gene encoding a single structural protein involved in these events. Moreover, the availability of forms of Brn-3a which stimulate cell survival and process outgrowth either separately or in parallel so would be of value in different situations where it is necessary to stimulate either both these processes or one without the other.

References Ace, C et ul. ( 1989). Construction and characterisation of a herpes simplex virus type I
mutant unable to transinduce immedicate early gene expression. .I Virol; 63:
260-2269.
Budhram-Mahadeo, V.S., Moms, P.J., Lalcin, N.D., Dawson, S.J. and Latchman, D.S.
( 1996). The different activities of the two activation domains of the Brn-3a transcription factor are dependent on the context of the binding site. J Biol Chem, 271:9108-1o Budhram-Mahadeo, V.S., Morris, P.J., Lakin, N.D., Theil, T., Ching, G.Y., Lillycrop, K.A., Moroy, T., Liem, R.K.H. and Latchman, D.S. (1995). Activation of the a-internexin promoter by the Brn-3a transcription factor is dependent on the N-terminal region of the protein. J Biol Chem, 270:2853-2858 i5 Budhram-Mahadeo, V.S., Theil, T., Mon:is, P.J., Lillycrop, K.A., Moroy, T.
and Latchman, D.S. (1994). The DNA target site for the Brn-3 POU family transcription factors can confer responsiveness to cyclic AMP and removal of serum in neuronal cells.
Nucl Acids Res, 22:3092-3098 2o Chen, H-M. and Boxer, L.M. (1995). ~I binding sites are negative regulators of Bcl-2 expression in pre-B cells. Mol Cell Biol, 15:3840-3847.
Chou, J. and Roizman, B. ( 1992). The 'y, 34.5 gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of 25 programmed cell death in neuronal cells. PNAS; 89: 3266-3270 Chou. J., Poon, APW, Johnson, J. and Roizman B. (1994). Differential response of human cells to deletions and stop codons in the y,34.5 gene of herpes simplex virus.
J. Virol., 68:
8304-8311.
Coffin, R.S. and Latchman, D.S. Herpes Simplex Virus based vectors. In:
Genetic manipulation of the nervous system, edited by Latchman, D.S. Academic Press, 1996, Coffin, R.S., Howard, M.K., Gumming, D.V.E., Dollery, C.M., McEwan, J., Yellon, D.M., Marber, M.S., Maclean, A.R., Brown, S.M. and Latchman, D.S (1996a). Gene delivery to cardiac cells in vitro and in vivo using herpes simplex virus vectors. Gene Therapy 3:560-566, Coffin, R.S., Maclean, A.R., Latchman, D.S. and Brown, S.M (1996b). Safe Delivery of a trans-gene to the mouse central or peripheral nervous system using HSV 1 ICP34.5 deletion mutant vectors. Gene Therapy 3:886-891.
1 o Davies, AM ( 1995). Cranial sensory neurons. In: Neuronal Cell Culture; A
Practical Approach (J Cohen and GP Wilkin, Eds.). IRL Press.
Dawson, S.J., Morris, P.J. and Latchman, D.S. (1996). A single amino acid change converts an inhibitory transaction factor into an activator. JBiol Chem, 271: 11631-11633.
Fsdtsova, N.G. and Turner, E.E. (1996). Brn-3.0 expression identifies early post-mitotic CNS neurons and sensory neuron precursors. Mechanisms of Development, 53:291-Gavrieli, Y, Sherman, Y, and Ben-Sasson, S.A. (1992..1. Cell. Biol., 119:493-501.
Howard, M.K., Burke, L.C., Mailhos, C., Pizzey, A., Gilbert, C.S., Lawson, W.D., Collins, M.K.L., Thomas, N.S.B. and Latchman, D.S (1993). Cell cycle arrest of proliferating neuronal cells by serum deprivation can result in either apoptosis or differentiation. Journal ofNeurochemistry 60:1783-1791.
Howard, M.K., Burke, L.C., Mailhos, C., Pizzey, A., Gilbert, C.S., Lawson, W.D., Collins, M.K.L., Thomas, N.S.B. and Latchman, D.S. (1993). Cell cycle arrest of proliferating neuronal cells by senun deprivation can result in either apoptosis or differentiation. J
Neurochem, 60:1783-1791.
Lakin, N.D., Morris, P.J., Theil, T., Sato, T.N., Moroy, T., Wilson, M.C. and Latchman, D.S. (1995). J. Biol. Chem. 270:15858-15863 wo 99ros2n rcrics9srozizs MacLean, A. et al ( 1991 ). Herpes simplex virus type I deletion variants 1714 and 1716 pinpoint neurovirulence related sequences in Glasgow strain 17+ between immediate early gene I and the 'a' sequence. J Gen Virol; 72: 632-639.
s Miyashita, T. and Reed, J. C. (1995). Cell; 80: 293-299.
Morgenstern, J.P. and Land, H. (1990a) Advanced gene transfer: high titre retroviral vectors with multiple drug selection markers and a completely helper-free packaging cell line. Nucl. Acids Res., 18:3587-3590.
~o Morgenstern JP and Land H. (1990b) A series of mammalian expression vectors and characterisation of their expression of a reporter gene in stably and transiently transfected cells. Nucl. Acids Res., 18: 1068.
15 Morris, P.J., Lakin, N.D., Dawson, S.J., Ryabanin, A.E., Kilimann, M.W., Wilson, M.C.
and Latchman, D.S (1997). Differential regulation of genes encoding synaptic proteins by members of the Brn-3 sub family of POU transcription factors. Molecular Brain Research 43, 279-28~.
2o Morris, P.J., Theil, T., Ring, C.J.A., Lillycrop, K.A., Moroy, T. and Latchman, D.S. (1994).
The opposite and antagonistic effects of the closely related POU transcription factors on the activity of a target promoter are dependent on differences in the POU domain.
Mol Cell Biol, 14, 6907-6914 2 5 Rice, S.A and Knipe, D.M ( 1990).. J. Virol 64: 1704-1715.
Sekulovich RE et al. (1990) J. Virol 64:3916-3926.
Smith, IL, Hardicke, MA, and Sandri-Goldin, RM ( 1992). Evidence that the herpes simplex s o virus immediate early protein ICP27 acts post-translationally during infection to regulate gene expression. Virology; 186: 74-86.

WO 99/OS2~2 PCT/GB98I02228 Smith, M.D., Dawson, S.J. and Latchman, D.S. (1997a). The Brn-3a transcription factor induces neuronal process outgrowth and the co-ordinate expression of genes encoding synaptic proteins. Mol Cell Biol, 17(1):345-354 s Smith, M.D., Dawson, S.J. and Latchman, D.S. (1997b). Inhibition of neuronal process outgrowth and neuronal specific gene activation by the Bm-3b transcription factor. J Biol Chem, 272(2):1382-1388 Smith, M.D., Moms, P.J., Dawson, S.J., Schwartz, M.L., Schlaepfer, W.W. and Latchman, 1 o D.S. (1997c) Co-ordinate induction of the three neurofilament genes by the Brn-3a transcription factor. J. Biol. Chem. 272:21325-21333.
Theil, T., McLean-Hunter, S., Zornig, M. and Moroy, T. (1993). Mouse Brn-3 family of POU transcription factors: a new amino terminal domain is crucial for the oncogenic 1 s activity of Brn-3a. Nucl Acids Res, 21:5921-5929 Theil, T., Zechner, U., Klett, C., Adolph, S. and Moroy, T. (1994}.
Chromosomal localization and cDNA sequences of the marine Brn-3 family of developmental control genes. Cytogeneticr and Cell Genetics, 66:267-271 Wood, J.N. et al. ( 1990). Novel cell lines display the properties of nociceptive sensory neurons. Proceedings of the Royal Society of London Series B, 241:187-194.
Xiang, M, Zhou, L, Macke, JP, Yoshioka, T, Hendry, SH, eddy, RL, Shows, TB, and 2s Nathans, J. (1995) The Brn-3 family of POU-domain factors: primary structure, binding specificity, and expression in subsets of retinal ganglion cells and somatosensory neurons.
JNeurosci, 7(1): 4762-4785.
Young, R.L. and Korsmeyer, S.J. 91993). A negative regulatory element in the Bcl-2 5' 3 o untranslated region inhibits expression from an upstream promoter. Mol Cell Biol, 13 3686-3697.

_.. _ _1_ SEQUENCE LISTING
SEQUENCE DESCRIPTION: SEQ ID NOs: 1 (polynucleotide) and 2 (amino acid):
- human Brn-3a TTT GCC CAT
CCC
ACC

Met Met Ser Met Asn Ser Lys Gln Pro His Met Pro Thr Phe Ala His TCC AGC GAG
GCC
ATC

Leu Pro Glu His Lys Tyr Pro Ser Leu His Ser Ala Ile Ser Ser Glu CAG AGC CTC

Arg Arg Ala Cys Leu Pro Thr Pro Pro Leu Asn Phe Ala Gln Ser Leu GAG GCG GCG

Ser Leu Asp Glu Thr Leu Leu Ala Arg Ala Leu Ala Yal Glu Ala Ala CCT TTC CCG

Asp Ile Ala Yal Ser Gln Gly Lys Ser His Lys Asp Ala Pro Phe Pro ACG TCC TCC

Thr Tyr His Thr Met Asn Ser Ya1 Pro Cys Thr Thr Yal Thr Ser Ser CAC CAC GCG

Pro Leu Arg His His His His His His His Gln Leu Glu His His Ala CCG TCG GCG

Pro Gly Asp Leu Leu Asp His Ile Ser Ser Leu Leu Met Pro Ser Ala GCG GCG GGC

Ala Gly Ala Gly Gly Ala Gly Gly Ala Gly Ala Gly Gly Ala Ala Gly GGC CCG GGC

Gly Ala His Asp Gly Pro Gly Gly Gly Gly Gly Gly Gly Gly Pro Gly GGC GGT GGC

Gly Pro Gly Gly Gly Gly Pro Gly Gly Gly Gly Pro Gly Gly Gly Gly CTG GGC TCC

Gly Gly Gly Gly Gly Pro Gly Gly Gly Leu Ala His Leu Gly Gly Ser CTG TCG CAC CCC

Pro His Pro His Met His Ser Leu Gly His Ala Ala Leu Ser His Pro SUBSTITUTE SHEET (RULE 26) ATG CCG
TCC

Ala AlaAla AsnMet ProSerGly LeuProHis ProGlyLeu Val Met GCG

Ala AlaAla HisHis GlyAlaAla AlaAlaAla AlaAlaAla Ala Ala GTG

Ala GlyGln AlaAla AlaSerAla AlaAlaAla ValValGly Ala Val GCG

A1a GlyLeu SerIle CysAspSer AspThrAsp ProArgGlu Leu Ala GCG

Glu AlaPhe GluArg PheLysGln ArgArgIle LysLeuGly Val Ala GAC

Thr GlnAla ValGly SerAlaLeu AlaAsnLeu LysIlePro Gly Asp CTC

Val GlySer SerGln SerThrIle CysArgPhe GluSerLeu Thr Leu AAC

Leu SerHis AsnMet IleAlaLeu LysProIle LeuGlnAla Trp Asn GCC

Leu GluGlu GluGly AlaGlnArg GluLysMet AsnLysPro Glu Ala GGC

Leu PheAsn GlyGlu LysLysArg LysArgThr SerIleAla Ala Gly CGC

Pro GluLys SerLeu GluAlaTyr PheAlaVal GlnProArg Pro Arg AAG

Ser SerGlu IleAla AlaIleAla GIuLysLeu AspLeuLys Lys Lys CGG TGG CAG

Asn ValVal ValTrp PheCysAsn GlnArgGln LysGlnLys Arg Arg AAA TCT ACT
TAC

Met LysPhe Tyr Ser Ala Thr SUBSTITUTE SHEET (RULE 26) __ _ _3_ SEQUENCE DESCRIPTION: SEQ ID NOs: 3 (polynucleotide) and 4 (amino acid):
- murine Brn-3a ATG AGC CCT

Met Ser MetAsn LysGln HisPhe AlaMetHis ProThr Met Ser Pro CCT TAC CTG

Leu Glu His'Lys ProSer HisSer SerSerGlu AlaIle Pro Tyr Leu CGG CCC CCG

Arg Ala CysLeu ThrPro LeuGln SerAsnLeu PheAla Arg Pro Pro CTG CTG CGG

Ser Asp GluThr LeuAla AlaGlu AlaLeuAla AlaVal Leu Leu Arg ATC CAG AGC

Asp Ala ValSer GlyLys HisPro PheLysPro AspAla Ile Gln Ser TAC AAT CCC

Thr His ThrMet SerVal CysThr SerThrSer ThrVal Tyr Asn Pro CTG CAC CAC

Pro Ala His.His HisHis HisHis HisGlnAla LeuGlu Leu His His GGT GAC TCG

Pro Asp LeuLeu HisIle SerPro SerLeuAla LeuMet Gly Asp Ser GGC GCA GCG

Ala Ala GlyGly GlyAla GlyGly GlyGlyGly AlaHis Gly Ala Ala GGC GGA CCG

Asp Pro GlyGly GlyGly GlyG1y GlyGlyGly ProGly Gly Gly Pro GGC GGT GGC

Gly Gly ProG1y GlyGly GlyGly GlyProGly GlyGly Giy Cly Gly GGC GGC TTG

Gly Ala ProGly GlyLeu GlyGly SerAlaHis ProHis Gly Gly Leu CAC CTG CTG

Pro Met HisGly GlyHis SerHis ProAlaAla AlaAla His Leu Leu ATG TCC CCG

Ala Asn MetPro GlyLeu HisPro GlyLeuVal AlaAla Met Ser Pro SUBSTITUTE SHEET (RULE 26) _. _ _q_ GCA GGG
GCG

AlaAla HisHisGly AlaAlaAla AlaAla AlaAla AlaAlaGly Ala GTG

GlnVal AlaAlaAla SerAlaAla AlaVal ValGly AlaAlaGly Ala ACG

LeuAla SerIleCys AspSerAsp AspPro ArgGlu LeuGluAla Thr CGC

PheAla GluArgPhe LysGlnArg IleLys LeuGly ValThrGln Arg AAC

AlaAsp YalGlySer AlaLeuAla LeuLys IlePro GlyYa1Gly Asn AGG

SerLeu SerGlnSer ThrIleCys PheGlu SerLeu ThrLeuSer Arg CCC

HisAsn AsnMetIle AlaLeuLys IleLeu GlnAla TrpLeuGlu Pro AAA

GluAla GluGlyAla GlnArgGlu MetAsn hysPro GluLeuPhe Lys CGG

AsnGly GlyGluLys LysArgLys ThrSer IleAla AlaProGlu Arg GCC

LysArg SerLeuGlu AlaTyrPhe YalGln ProArg ProSerSer Ala AAA

GluLys IleAlaAla IleAlaGlu LeuAsp LeuLys LysAsnYal Lys AGA

YalArg ValTrpPhe CysAsnGln GlnLys GlnLys ArgMetLys Arg PheSer AlaThrTyr SUBSTC~UTE SHEET (RULE 26)

Claims (30)

1. A polypeptide comprising a derivative of transcription factor Brn-3a which derivative possesses anti-apoptotic activity but not neurite outgrowth stimulating activity for use in a method of treatment of the human of animal body by therapy.
2. 2. A polypeptide according to claim 1 wherein said derivative comprises an N-terminal fragment of Brn-3a.
3. 3. A polynucleotide encoding a polypeptide according to claim 1 or 2 for use in a method of treatment of the human or animal body by therapy.
4. 4. A nucleic acid vector comprising a polynucleotide according to claim 3 operably linked to regulatory sequences permitting expression of said polypeptide in a host cell, for use in a method of treatment of the human or animal body by therapy.
5. 5. A vector according to claim 4 wherein said host cell is a cell of the central or peripheral nervous system of a mammal.
6. 6. A vector according to claim 4 or 5 further comprising mammalian genomic sequences flanking said polynucleotide and regulatory sequences.
7. 7. A vector according to claim 5 or 6 further comprising viral genomic sequences flanking said polynucleotide and regulatory sequences.
8. 8. A viral strain comprising a polynucleotide according to claim 3 operably linked to regulatory sequences permitting expression of a polypeptide encoded by said polynucleotide in a host cell, for use in a method of treatment of the human or animal body by therapy.
9. 9. A viral strain according to claim 8 wherein said viral strain is a herpes simplex virus strain.
10. 10. A composition comprising a polynucleotide according to claim 3, a vector according to any one of claims 4 to 7 or a viral strain according to claim 8 or 9 together with a transfection agent, for use in a method of treatment of the human or animal body by therapy.
11. 11. A composition according to claim 10 wherein said transfection agent is a cationic agent or a liposome composition.
12. 12. A composition comprising a polypeptide according to claim 1 or 2 and at least one other therapeutic polypeptide, for use in a method of treatment of the human or animal body by therapy.
13. 13. A composition comprising a polynucleotide according to claim 3 and at least one other polynucleotide encoding a therapeutic polypeptide, for use in a method of treatment of the human or animal body by therapy.
14. 14. A composition comprising a vector according to any one of claims 4 to 7 and a vector comprising a polynucleotide encoding a second therapeutic polypeptide operably linked to a regulatory sequence permitting expression of said factor in a host cell, for use in a method of treatment of the human or animal body by therapy.
15. 15. A composition comprising a viral strain according to claim 8 or 9 and a viral strain comprising a polynucleotide encoding a second therapeutic polypeptide, for use in a method of treatment of the human or animal body by therapy.
16. 16. A viral strain comprising a polynucleotide encoding a polypeptide according to claim 1 or 2 and a polynucleotide encoding a second therapeutic polypeptide.
17. 17. A composition according to any one of claims 12 to 15 or a viral strain according to claim 16 wherein said second therapeutic polypeptide is a neurotrophic factor.
18. 18. A pharmaceutical composition comprising a polypeptide according to claim 1 or 2, a polynucleotide according to claim 3, a vector according to any one of claims 4 to 7, a viral strain according to claim 8, 9 or 16, or a composition according to any one of claims 10 to 15 or 17, together with a pharmaceutically acceptable carrier or diluent.
19. 19. A polypeptide according to claim 1 or 2, a polynucleotide according to claim 3, a vector according to any one of claims 4 to 7, a viral strain according to claim 8, 9 or 16, a composition according to any one of claims 10 to 15 or 17 or a pharmaceutical composition according to claim 18, for use in preventing apoptosis in a cell of the peripheral or central nervous system of a human or animal
20. 20. A polypeptide, a polynucleotide, a vector, a viral strain, a composition or a pharmaceutical composition according to claim 19 for use in a method of treatment of a neurogenerative disorder.
21. 21. A polypeptide, a polynucleotide, a vector, a viral strain, a composition or a pharmaceutical composition according to claim 20, wherein said neurodegenerative disorder is motor neurone disease, familial dysautonomia, infantile spinal muscular atrophy, Parkinson's disease or Alzheimer's disease.
22. 22. A method of preventing apoptosis in a cell of the peripheral or central nervous system of a human or animal, which method comprises administering to the human or animal a therapeutically effective amount of a polypeptide according to claim 1 or 2. a polynucleotide according to claim 3, a vector according to any one of claims 4 to 7, a viral strain according to claim 8, 9 or 16, a composition according to any one of claims 10 to 15 or 17 or a pharmaceutical composition according to claim 18.
23. 23. A polypeptide as defined in claim 1 or 2, a polynucleotide as defined in claim 3, a vector as defined in any one of claims 4 to 7, a viral strain as defined in claim 8, 9 or 16, a composition as defined in any one of claims 10 to 15 or 17 or a pharmaceutical composition as defined in claim 18.
24. 24. Use of a polypeptide comprising transcription factor Brn-3a or a derivative thereof in the manufacture of a medicament for use in a method of preventing apoptosis in a cell of the peripheral or central nervous system of a human or animal.
25. 25. Use according to claim 24, wherein said derivative is a Brn-3a derivative as defined in claim 1 or 2.
26. 26. Use of a polynucleotide encoding a polypeptide as defined in claim 24 or 25 in the manufacture of a medicament for use in a method of preventing apoptosis in a cell of the peripheral or central nervous system of a human or animal.
27. 27. Use of a nucleic acid vector comprising a polynucleotide as defined in claim 26 in the manufacture of a medicament for use in a method of preventing apoptosis in a cell of the peripheral or central nervous system of a human or animal.
28. 28. Use of a viral strain comprising a polynucleotide as defined in claim 26 in the manufacture of a medicament for use in a method of preventing apoptosis in a cell of the peripheral or central nervous system of a human or animal.
29. 29. Use according to any one of claims 24 to 28 for use in a method of treatment of a neurodegenerative disease.
30. 30. Use according to claim 29 for use in a method of treatment of motor neurone disease, familial dysautonomia, infantile spinal muscular atrophy, Parkinson's disease or Alzheimer's disease.